Influenza vaccine coverage in 6months-64 years-old patients affected by chronic diseases: A retrospective cohort study in Italy

ABSTRACT At the beginning of each flu season, the Italian Ministry of Health defines the categories at higher risk of influenza complications, for which vaccination is actively and freely offered. The vaccine coverage (VC) of the influenza vaccine in subjects from 6 months to 64 years of age suffering from diseases that increase the risk of complications from influenza during the 2020–2021 season was evaluated. Our study wants to evaluate the VCs of the influenza vaccine in these subjects during the 2020/2021 season in Apulia. The digital archives relative to the Apulian population were used. A retrospective cohort study design was performed. 484,636 Apulian residents aged between 6 months and 64 years suffered from at least one chronic disease; 139,222 of 484,636 subjects received the influenza vaccine (VC: 28.7%) from October 2020 to January 2021. Considering the single comorbidities, the greatest values are found for pathologies for which major surgical interventions are planned and chronic renal failure/adrenal insufficiency patients, while the worst for chronic liver diseases and pathologies for which major surgical interventions are planned. In any case, it would seem that better VC is achieved in subjects with more than one chronic condition. Influenza vaccination must be promoted as a central public health measure, also because by reducing the burden on hospitals, it can greatly benefit the management of COVID-19 patients. Greater efforts by public health institutions must be implemented in order to achieve better VC in the target categories, including chronic patients.

[1]  L. Vimercati,et al.  Two years of on-site influenza vaccination strategy in an Italian university hospital: main results and lessons learned , 2021, Human vaccines & immunotherapeutics.

[2]  W. Chan,et al.  Vaccinations and inflammatory bowel disease - a systematic review. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  S. Tafuri,et al.  Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study , 2021, Vaccines.

[4]  P. Lopalco,et al.  Influenza Vaccination and Health Outcomes in COVID-19 Patients: A Retrospective Cohort Study , 2021, Vaccines.

[5]  M. Gulati,et al.  Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta‐Analysis , 2021, Journal of the American Heart Association.

[6]  S. Tafuri,et al.  Immunization coverage among asplenic patients and strategies to increase vaccination compliance: a systematic review and meta-analysis , 2021, Expert review of vaccines.

[7]  E. Sagnelli,et al.  Low influenza vaccination coverage in subjects with liver cirrhosis. An alert waiting for winter season 2020–2021 during the COVID‐19 pandemic , 2020, Journal of medical virology.

[8]  M. Postma,et al.  Health Economics of Vaccines: From Current Practice to Future Perspectives , 2020, Value in Health.

[9]  F. Meloni,et al.  Vaccination against seasonal influenza and socio-economic and environmental factors as determinants of the geographic variation of COVID-19 incidence and mortality in the Italian elderly , 2020, Preventive Medicine.

[10]  G. Campo,et al.  Influenza coverage rates in subjects with chronic heart diseases: results obtained in four consecutive immunisation seasons in the Local Health Unit of Ferrara (North Italy)” , 2020, Archives of Public Health.

[11]  L. Grohskopf,et al.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season , 2020, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[12]  A. Falsey,et al.  The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies , 2020, Vaccine.

[13]  Eduardo Missoni,et al.  The Italian health system and the COVID-19 challenge , 2020, The Lancet Public Health.

[14]  Q. S. Huang,et al.  Risk of Severe Influenza among Adults with Chronic Medical Conditions. , 2019, The Journal of infectious diseases.

[15]  C. Parisinos,et al.  Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis , 2019, BMJ Open.

[16]  S. Klein,et al.  Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs , 2019, Journal of Virology.

[17]  L. Brammer,et al.  Update: Influenza Activity in the United States During the 2018–19 Season and Composition of the 2019–20 Influenza Vaccine , 2019, MMWR. Morbidity and mortality weekly report.

[18]  S. Tafuri,et al.  Influenza vaccination coverage among splenectomized patients: an Italian study on the role of active recall in the vaccination compliance , 2019, Human vaccines & immunotherapeutics.

[19]  C. P. Pelullo,et al.  Seasonal influenza: Knowledge, attitude and vaccine uptake among adults with chronic conditions in Italy , 2019, PloS one.

[20]  R. Prato,et al.  Using Routine Data Sources to Feed an Immunization Information System for High-Risk Patients—A Pilot Study , 2018, Front. Public Health.

[21]  E. Gianchecchi,et al.  Influenza vaccines: Evaluation of the safety profile , 2018, Human vaccines & immunotherapeutics.

[22]  M. Levi,et al.  The “Fluad Case” in Italy: Could it have been dealt differently? , 2017, Human vaccines & immunotherapeutics.

[23]  O. Manuel,et al.  Influenza vaccination in immunocompromised patients: efficacy and safety. , 2014, Immunotherapy.

[24]  J. Yee,et al.  Vaccination in Chronic Kidney Disease. , 2019, Advances in chronic kidney disease.